Results from first-time tests of a multibiomarker disease activity score for RA reported

Researchers from two Pfizer-sponsored studies reported successful, first-time tests of a multibiomarker disease activity score in patients with rheumatoid arthritis. The studies examined Pfizer’s adalimumab and infliximab biosimilars, finding that serum biomarker levels tracked one another closely between biosimilar and reference cohorts reducing the need for physical examinations.